黑色素瘤个体化mRNA疫苗三期临床成效显着
黑色素瘤个体化mRNA疫苗三期临床成效显着
Conclusion
The surge has a real clinical catalyst behind it—but not evidence yet that the cancer-vaccine approach works across cancers. In resected melanoma, Moderna and Merck have reported positive Phase 3 results for intismeran autogene (V940, formerly mRNA-4157) plus pembrolizumab: the combination improved recurrence-free and distant metastasis-free survival versus pembrolizumab alone. The lung and kidney programs are still trials, not demonstrated extensions of that benefit. Data checked through 28 October 2026.
What the companies have disclosed
Intismeran is an investigational, individualized neoantigen therapy, not a preventive vaccine. A patient’s tumor is analyzed to select mutations for a bespoke mRNA treatment intended to prompt a T-cell response; the design can encode up to . It is being developed jointly by Moderna and Merck, usually alongside pembrolizumab.
The most important new disclosure is the Phase 3 INTerpath-001 melanoma result. At a median follow-up of , the trial reported:
- Recurrence-free survival (RFS): HR , 95% CI , .
- Distant metastasis-free survival (DMFS): HR , 95% CI , .
- At two years, RFS was versus ; DMFS was versus .
These results are from a randomized Phase 3 trial of with completely resected, high-risk stage IIB–IV cutaneous melanoma. The comparator was pembrolizumab alone. The result is meaningful because it moves the melanoma evidence beyond the earlier, smaller Phase 2b study.
There is an important qualification: the benefit was not apparent in the prespecified analysis of the first six months. The RFS HR was during that period, versus 0.42 after six months. That later-period result is a sensitivity analysis, not a substitute for the trial’s primary overall result, but it matters when considering treatment timing and the durability of benefit.
The earlier KEYNOTE-942 Phase 2b results provide supporting follow-up, not the same level of confirmation. The study randomized ; its planned five-year analysis was explicitly descriptive. The combination’s RFS HR was (95% CI ) and its DMFS HR was (95% CI ). The exploratory overall-survival estimate was much less certain: HR , 95% CI —an interval that includes no effect.
How strong is the evidence?
Melanoma: encouraging and now substantially more credible, because the Phase 3 study was randomized and reported statistically significant RFS and DMFS results against an active standard-of-care comparator. But overall-survival data remain immature. Conference coverage of the ESMO presentation reported an OS HR of , with a 95% CI of and ; that is not a statistically significant OS result. The companies said follow-up is continuing.
Lung and kidney: there is evidence of development activity, but no lung- or kidney-cancer efficacy result in the company announcements and trial records reviewed here. The latest company release described nine Phase 2 and Phase 3 trials across cancer types and reported three ongoing Phase 3 NSCLC trials. Separately, the registry lists INTerpath-002 as a Phase 3 lung study, with estimated primary completion on . The randomized renal-cell-carcinoma study, INTerpath-004, is Phase 2, with estimated primary completion on . These are registry estimates, not promised readout dates. The bladder program is earlier-stage: its listed study is Phase 1/2.
That distinction matters. A positive result in melanoma supports the treatment concept in that setting; it does not establish efficacy in lung or kidney cancers. Those indications require their own trial results.
Investor milestones and risks
Milestones to watch
- Further OS follow-up and the regulatory path for the melanoma use. The companies reported engaging with regulators, but the releases reviewed do not give a firm filing or approval date.
- The next efficacy results from the lung trials, and the Phase 2 renal-cell-carcinoma study. These would test whether the melanoma result transfers to other diseases.
- The accepted-for-publication Phase 3 melanoma paper and the detailed conference data, which allow closer scrutiny of endpoints, subgroups, safety and treatment delivery.
Risks to the thesis
- Personalization may constrain delivery. Conference coverage reported that of screened patients were excluded because their tumor sample was inadequate, and the median time to the first vaccine dose was . Manufacturing succeeded for more than of patients randomized to the combination arm, but reliable manufacture after enrollment does not remove the screening and turnaround hurdles.
- Treatment burden and adverse events. In INTerpath-001, treatment-related Grade 3–5 adverse events were with the combination and with pembrolizumab alone. Conference coverage also reported treatment-related adverse events leading to discontinuation of any study drug in versus . Fever and injection-site reactions were common with the combination.
- No survival proof yet. RFS and DMFS are positive, but the OS result is immature and not statistically significant at the reported analysis. In an adjuvant setting, confirmation of durable benefit remains important.
- Valuation can outrun evidence. A Phase 3 melanoma win can rationally increase expectations for a differentiated oncology product and a broader platform. But lung and kidney sales, approvals, launch timing and commercial economics remain uncertain; the existence of trials is not evidence of clinical benefit in those cancers.
Bottom line: the melanoma data are a meaningful clinical de-risking event, not merely a speculative “cancer-vaccine” story. The stronger platform-wide investment claim is still a hypothesis: the next decisive evidence is whether disease-specific trials reproduce benefit, while melanoma OS, regulatory progress and bespoke manufacturing feasibility remain unresolved.